Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Juggling Gene Therapies: Sarepta's Focus Grows, With Many Balls In The Air

Executive Summary

CEO Doug Ingram talked with Scrip about Sarepta's plans to quickly build out a gene therapy pipeline, potentially launch another exon-skipping drug this year and to develop micro-dystrophin for Duchenne muscular dystrophy.

You may also be interested in...



Sarepta Surprised By CRL For Exon 53-Skipping DMD Drug Golodirsen

The US FDA issued a complete response letter rejecting golodirsen based on risk of infection at intravenous infusion ports and preclinical renal toxicity.

Capricor’s Interim Data Could Offer Hope For Older DMD Patients

Although only interim data from six treated patients, Capricor’s Phase II DMD study shows improvements in upper limb performance, grip strength and respiration. Cardiac performance shows positive trend, but not yet statistical significance.

Heralding Change: Product Pipeline Advances To Watch Out For In Q3

Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel